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Background: Anti-epidermal growth factor receptor (EGFR)-monoclonal antibodies (MoAbs) have been widely used
in a variety of malignancies. Severe infections (≥grade 3) are potentially life-threatening adverse events with these
drugs. However, the contribution of anti-EGFR MoAbs to infections is still unknown. We performed this meta-analysis to
determine the overall incidence and risk of severe infections in cancer patients treated with these drugs.
Methods: The databases of PubMed and abstracts presented at oncology conferences and published in the
proceedings were searched for relevant studies from January 2000 to May 2014. Summary incidences, relative risks
(RRs) and 95% confidence intervals (CIs) were calculated by using either random effects or fixed effect models
according to the heterogeneity of included studies.
Results: A total of 14,066 patients from 26 randomized controlled trials (RCTs) were included. The use of
anti-EGFR-MoAbs significantly increased the risk of developing severe infections (RR 1.34, 95%CI: 1.10 to 1.62, P = 0.003)
in cancer patients, but not for fatal infections (RR 1.62, 95%CI: 0.81 to 3.26, P = 0.18). Meta-regression indicated the
infections might possibly occur early in the treatment with anti-EGFR MoAbs. On sub-group analysis, the risk of severe
infections significantly varied with tumor type (P = 0.001). When stratified by specific anti-EGFR MoAbs, a significantly
increased risk of infections with cetuximab was observed (P <0.001), but not for panitumumab (P = 0.98). Additionally,
the use of anti-EGFR MoAbs significantly increased the risk of severe infections when used in conjunction with
cisplatin (RR 1.48, 95%CI 1.22 to 1.79, P <0.001) or irinotecan (RR 1.53, 95%CI 1.12 to 2.10, P = 0.008). When
stratified by specific infectious events, anti-EGFR-MoAbs significantly increased the risk of developing severe
sepsis (RR 4.30, 95%CI: 1.80 to 10.27; P = 0.001).
Conclusions: Anti-EGFR MoAbs treatment significantly increases the risk of developing severe infectious events
in cancer patients. The risk may vary with tumor types. Clinicians should be aware of the risks of severe
infections with the administration of these drugs in cancer patients.
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The epidermal growth factor receptor (EGFR) signal path-
way plays an essential role in tumor proliferation, differenti-
ation, anti-apoptosis and metastasis [1-3]. For this reason,
EGFR and the process of its receptor binding are regarded
as attractive therapeutic targets in the treatment of cancers.
Currently, two monoclonal antibodies (MoAbs) targeted
at EGFR, the chimeric immunoglobulin G1 (IgG1) MoAb
cetuximab and the fully humanized IgG2 MoAb panitumu-
mab, have shown a relevant clinical effect in the treatment
of a variety of malignancies. Cetuximab has been approved
by the US Food and Drug Administration (FDA) for the
treatment of metastatic colorectal cancer [4] and recurrent
or metastatic head and neck cancer [5]. Panitumumab is
approved by the FDA for the indication of advanced colo-
rectal cancer [6].
In contrast with traditional chemotherapy agents,
anti-EGFR-MoAbs do not usually produce systemic toxic-
ities such as nausea, vomiting, diarrhea, alopecia, and bone
marrow suppression. However, anti-EGFR-MoAbs exhibit
some unique toxicities including rash [7,8], hypomag-
nesemia [9-11], hypokalemia [12] and venous and arterial
thromboembolic events [11]. Specifically, severe infections
(≥grade 3) are reported in both cetuximab and panitu-
mumab trials as a common side effect, as a cause of
treatment disruption, and in some cases led to fatalities
[13-15]. However, to the best of our knowledge, the inci-
dence and risk of severe infections with these drugs have
not been systematically defined. Therefore, we performed
this up-to-date meta-analysis of randomized controlled
trials to determine whether the addition of anti-EGFR-
MoAbs to therapies increases the risk of severe and fatal
infections in cancer patients.
Methods
Data sources
We searched the PubMed (data from 2000 to May 2014),
Embase (data from 2000 to May 2014) and the Cochrane
Library electronic databases. Key words were ‘cetuximab’,
‘Erbitux’, ‘panitumumab’, ‘Vectibix’, ‘cancer’, ‘carcinoma’,
‘neoplasm’, ‘randomized controlled trial’ and ‘infections’.
The search was limited to prospective randomized
clinical trials published in English. We also searched
abstracts containing the term ‘cetuximab’ and ‘panitu-
mumab’ that were presented at the American Society
of Clinical Oncology (ASCO) and European Society of
Medical Oncology (ESMO) annual meetings from
2004 to 2014 to identify relevant studies. Additionally,
we searched the clinical trial registration website [16]
to obtain information on registered prospective trials.
Each publication was reviewed and in cases of dupli-
cate publications only the most complete, recent and
updated report of the clinical trial was included in the
meta-analysis.Study selection
The primary goal of our study was to determine the
overall incidence of severe and fatal infections (≥grade 3)
associated with approved anti-EGFR-MoAbs (cetuximab
and panitumumab) and establish the association between
treatment with anti-EGFR-MoAbs and the risk of devel-
oping severe and fatal infections. Thus, only prospective
randomized controlled phase II and III trials evaluating
approved anti-EGFR-MoAbs (cetuximab and panitumumab)
in cancer patients with adequate data on severe or fatal
infections were incorporated in the analysis. Phase I and
single-arm phase II trials were excluded due to lack of
control groups. Clinical trials that met the following criteria
were included: (1) prospective randomized controlled phase
II or III trials involving cancer patients; (2) participants
assigned to treatment with or without approved anti-
EGFR-MoAbs (cetuximab and panitumumab) in addition
to concurrent chemotherapy, radiotherapy or biological
agent; and (3) available data regarding events or incidence
of severe or fatal infections and sample size.
Data extraction and clinical end point
Data abstraction was conducted independently by two
investigators (WXQ and SF), and any discrepancy between
the reviewers was resolved by consensus. For each study,
the following information was extracted: first author’s
name, year of publication, phase of trials, number of
enrolled subjects, treatment arms, number of patients
in treatment and control groups, underlying malignancy, me-
dian age, median treatment duration, median progression-
free survival, median overall survival and adverse outcomes
of interest (severe and fatal infections). The following adverse
outcomes were considered as infectious events and were
included in the analyses: infections (not specified), febrile
neutropenia, sepsis, septic shock, and pneumonia. Adverse
events of severe infections (≥grade 3), as assessed and
recorded according to the National Cancer Institute’s
common terminology criteria (NCI-CTC) version 2 or 3
[17], which has been widely used in cancer clinical trials,
were extracted for analysis.
Statistical analysis
For the calculation of incidence, the number of patients
with infections in the anti-EGFR-MoAbs group and the
total number of patients receiving anti-EGFR-MoAbs were
extracted from the selected clinical trials; the proportion of
patients with infections and 95% confidence interval (CI)
were derived for each study. To calculate relative risk (RR),
patients assigned to anti-EGFR-MoAbs were compared
only with those assigned to control treatment in the same
trial. For one study that reported zero events in the treat-
ment or control arm, we applied the classic half-integer
correction to calculate the RR and variance [18]. We also
conducted the following pre-specified subgroup analyses to
Qi et al. BMC Medicine 2014, 12:203 Page 3 of 12
http://www.biomedcentral.com/1741-7015/12/203find the potential risk factor of infections: tumor types,
anti-EGFR-MoAbs, concomitant therapies and phase of
trials. To assess the stability of results, sensitivity analysis
was performed by sequential omission of individual stud-
ies. Additionally, to test whether effect sizes were moder-
ated by differences in length of treatment, we have carried
out meta-regressions with the difference in median length
of experimental treatments (expressed in weeks) as the pre-
dictor and RR as the dependent variable. Between-study
heterogeneity was estimated using the χ2-based Q statistic
[19]. Heterogeneity was considered statistically significant
when Pheterogeneity <0.1. If heterogeneity existed, the pooled
estimate calculated based on the random-effects model was
reported using the DerSimonian et al. method [20]. In the
absence of heterogeneity, the pooled estimate calculated
based on the fixed-effects model was reported using the
inverse variance method. A statistical test with a P-value
less than 0.05 was considered significant. The presence
of publication bias was evaluated by using the Begg and
Egger tests [21]. All statistical analyses were performed
by using Version 2 of the Comprehensive MetaAnalysis
program (Biostat, Englewood, NJ, USA) and Open




Our search yielded 190 clinical studies relevant to
cetuximab and panitumumab. After excluding review
articles, phase I studies, single-arm phase II trials, case
reports, editorials, meta-analyses and systematic reviews
(Figure 1), we selected 26 randomized controlled trialsFigure 1 Selection process for prospective randomized controlled tria(RCTs), which included 17 phase III and 9 phase II trials. A
total of 14,060 patients from 26 RCTs were included for
analysis. The characteristics of the patients and studies are
listed in Table 1. According to the inclusion criteria of each
trial, patients were required to have adequate hepatic, renal
and hematological function. Underlying malignancies
included colorectal cancer (eleven trials) [14,15,22-31],
non-small-cell lung cancer (seven trials) [32-38], head
and neck cancer (four trials) [5,13,39,40], breast cancer
(one trial) [41], urothelial carcinoma (one trial) [42],
pancreatic cancer (one trial) [43] and esophagogastric
cancer (one trial) [44].
Overall incidence of severe and fatal infections
For calculating the incidence of severe infections, a
total of 6,446 patients from 26 RCTs who received
anti-EGFR-MoAbs were included for analysis. Using a
random-effects model, the summary incidence of severe in-
fection was 8.1% (95%CI, 6.0 to 10.9%). In addition, severe
infections can be fatal in many instances. A total of 5,239
patients from 16 RCTs were included for analysis of fatal
infections. Fatal infections occurred in 24 patients, repre-
senting a total incidence of 0.8% (95%CI: 0.5% to 1.2%).
Among patients with anti-EGFR MoAbs-associated severe
infections, meta-analysis showed that the mortality of
severe infections associated with anti-EGFR MoAbs was
4.0% (95%CI: 2.7 to 5.9%).
Relative risk of severe and fatal infections
To determine the specific contribution of anti-EGFR
MoAbs to the development of infections and to exclude
the effect of any confounding factors, we calculated thels included in the meta-analysis.


















Burtness B. et al./2005/III Head and
neck cancer
117 Cetuximab + DDP 60.6 4.5 4.2 9.2 58 15 Infections
Placebo + DDP 58.3 3 2.7 8 58 10
Bonner J.A. et al./2006/III Head and
neck cancer
424 Cetuximab + radiotherapy 56 8 24.4 49 208 1 Infections
Radiotherapy 58 NR 14.9 29.3 212 1
Jonker D. J. et al./2007/III CRC 572 Cetuximab + BSC 63 8.1 NR 6.1 288 37 Infections
BSC 63.6 NR NR 4.6 274 15
Borner M. et al./2008/II CRC 74 Cetuximab + oxaliplatin +
capecitabine
60 18 7.2 20.5 37 0 Febrile neutropenia
Oxaliplatin + capecitabine 63 18 5.8 16.5 37 0
Rosell R. et al./2008/II NSCLC 86 Cetuximab + NVB + DDP 58 13.6 5 8.3 42 7 Infections
NVB + DDP 57 12 4.6 7.3 43 2
Sobrero A.F. et al./2008/III CRC 1298 Cetuximab + irinotecan 61 14 4 10.7 638 49 Febrile neutropenia
Irinotecan 62 13.1 2.6 10 629 39
Vermorken J.B. et al./2008/III Head and
neck cancer
422 Cetuximab + platinum + FU 56 18 5.6 10.1 219 28 Febrile neutropenia,
pneumonia, sepsis
Platinum + FU 57 15 3.3 7.4 215 15
Lienbaum R. et al./2009/II NSCLC 64 Cetuximab + PTX NR 16 3.4 NR 30 1 Infections
Bortezomib + PTX NR 8 1.9 NR 29 1
Pirker R.et al./2009/III NSCLC 1125 Cetuximab + NVB + DDP 59 18 NR 11.3 548 129 Febrile neutropenia,
sepsis
NVB + DDP 60 14 NR 10.1 562 90
Tol J. et al./2009/III CRC 755 Cetuximab + capecitabine +
oxaliplatin + Bev
62 30 10.7 20.3 366 22 Infections
Capecitabine + oxaliplatin + Bev 62 25.7 9.4 19.4 366 25
Lynch T.J. et al./2010/III NSCLC 676 Cetuximab + chemotherapy 64 13 4.4 9.69 325 15 Febrile neutropenia
Chemotherapy 65 12 4.24 8.38 320 11
Govindan R. et al./2011/II NSCLC 101 Cetuximab + chemoradiotherapy 66 NR 12.3 22.2 53 9 Febrile neutropenia,
pneumonia,
Chemoradiotherapy 65 NR 12.6 22.4 50 10
Alberts S.R. et al./2012/III CRC 2686 Cetuximab + FOLFOX NR NR NR NR 931 96 Infections, febrile
neutropenia,


















Table 1 Baseline characteristics of 26 randomized controlled trials in the meta-analysis (number = 14,060) (Continued)
Dewdney A. et al./2012/II CRC 165 Cetuximab + capecitabine +
oxaliplatin + radiotherapy
65 NR NR NR 83 1 Febrile neutropenia
Capecitabine + oxaliplatin +
radiotherapy
61 NR NR NR 81 1
Saltz L. et al./2012/III CRC 247 Cetuximab + Bev + FOLFOX 63.2 NR 8.3 19.5 121 1 Sepsis
Bev + FOLFOX 61.2 NR 11 21.3 118 1
Baselga J. et al./2013/II MBC 181 Cetuximab + DDP 53 13.6 3.7 12.9 114 2 Sepsis
DDP 52 13.1 1.5 9.4 57 0
Kim E.S. et al./2013/III NSCLC 605 Cetuximab + Pemetrexed 64 NR 2.9 6.9 292 35 Infections, lung
infections, sepsis
Pemetrexed 65 NR 2.8 7.8 289 23
Burtness B. et al./2014/II Pancreatic
cancer
87 Cetuximab + Doc + irinotecan 60 16.5 4.5 6.5 45 5 Febrile neutropenia,
infections
Doc + irinotecan 60 14.5 3.9 5.3 46 4
Huang J. et al./2014/III CRC 146 Cetuximab + FOLFIRI 57 NR NR NR 40 3 Infections, febrile
neutropenia
FOLFIRI 59 NR NR NR 106 3
Hussain M. et al./2014/II Urothelial
carcinoma
88 Cetuximab + GEM + DDP 60.9 21.4 7.6 14.3 59 7 Infections, pneumonia
GEM + DDP 65.8 21.4 8.5 17.4 28 3
van den Heuval M.M. et al./2014/II NSCLC 102 Cetuximab + chemoradiotherapy 62 NR NR NR 51 3 Pneumonia
Chemoradiotherapy 63 NR NR NR 51 0
Douillard J.Y. et al./2010/III CRC 1183 Panitumumab + FOLFOX4 NR 20 9.6 23.9 539 15 Febrile neutropenia
FOLFOX4 NR NR 8.6 19.7 545 14
Peeters M. et al./2010/III CRC 1186 Panitumumab + FOLFIRI NR NR 5.9 14.5 539 9 Febrile neutropenia
FOLFIRI NR NR 3.9 12.5 540 16
Seymour M. T. et al./2013/III CRC 460 Panitumumab + irinotecan 64 12 NR 10.4 219 42 Infections
Irinotecan 63 12 NR 10.5 218 22
Vermorken J.B. et al./2008/III Head and
neck cancer
657 Panitumumab + DDP + FU 58 18.3 5.8 11.1 325 20 Febrile neutropenia
DDP + FU 59 NR 4.6 9 325 17
Waddell T. et al./2013/III Esophagogastric
cancer
553 Panitumumab + epirubicin +
oxaliplatin + capecitabine
63 15 7.4 8.8 276 48 Infection, febrile
neutropenia
Epirubicin + oxaliplatin +
capecitabine
62 15 6 11.3 266 70
Bev, bevacizumab; BSC, best support care; CRC, colorectal cancer; DDP, cisplatin; Doc, docetaxel; FOLFIRI, folinic acid (leucovorin), fluorouracil and irinotecan; FOLFOX, folinic acid (leucovorin), fluorouracil and
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RR of severe infections, 26 RCTs, representing 14,060
patients, were included. Among the 6,446 patients treated
with anti-EGFR MoAbs, 601 presented with severe in-
fections, whereas 438 of 6,359 patients in control groups
had a severe infectious event. This conferred an overall
RR of developing severe infections of 1.34 (95%CI, 1.10
to 1.62; P = 0.003; Figure 2). Significant heterogeneity
was observed in the RR analysis of severe infectious
events (Q = 44.99; P = 0.006; I2 = 46.7%). Considering
fatal infectious events, 24 of 5,239 patients treated with
anti-EGFR MoAbs and 11 of 4,940 patients in control
arms experienced a fatal infection. This conferred an
overall RR of 1.61 (95%CI, 0.81 to 3.25; P = 0.18). No
significant heterogeneity was observed in the RR analysis
of fatal infections (Q = 6.64; P = 0.88; I2 = 0%). We also
performed a sensitivity analysis to examine the stability
and reliability of pooled severe RRs by sequential omis-
sion of individual studies. The results indicated that the
significance estimate of pooled severe RRs was not signifi-
cantly influenced by omitting any single study (Figure 3).
Additionally, a meta-regression analysis was carried out
to test whether the RR of severe infections varied as a
function of difference in the length of the experimental
treatments. The result indicated that the RR of severe
infections tended to be lower in the study in which the
experimental treatment was longer, and this effect was
statistically significant (P = 0.02, Figure 4).Figure 2 Relative risk of severe infections associated with anti-EGFR M
MoAbs, monoclonal antibodies.Sub-group analysis for relative risk of severe infections
To determine whether the observed increase in RRs of
developing severe infections was the result of confounding
bias, we performed subgroup analyses according to the
underlying malignancy, anti-EGFR-MoAbs, concomitant
drugs and phase of trials. When stratified by tumor types,
a significantly increased risk of severe infections was
observed in colorectal cancer (RR1.42, 95%: 1.05 to
1.93, P = 0.024), non-small-cell lung cancer (RR1.45,
95%: 1.19 to 1.77, P <0.001) and head and neck cancer
(RR1.48, 95%: 1.02 to 2.13, P = 0.037), while the risk of
severe infections was decreased in other tumor types
(RR 0.72, 95%CI: 0.53 to 0.97, P = 0.033, Table 2). In
addition, significant differences in RRs of severe infections
were found among these tumor types (P = 0.001). How-
ever, clinicians should be cautious when interpreting these
results due to limited RCTs of other tumor types included
for the RR calculation.
The risk of severe infections might be related to different
anti-EGFR MoAbs. Our results demonstrated that the
use of cetuximab significantly increased the risk of severe
infections (RR 1.52, 95%CI: 1.33 to 1.75, P <0.001), while
the use of panitumumab did not increase the risk of severe
infections (RR 0.99, 95%CI: 0.62 to 1.60, P = 0.98). Then,
we also carried out a subgroup risk analysis stratified ac-
cording to concomitant therapies with anti-EGFR-MoAbs.
A significantly increased risk of severe infections with anti-
EGFR-MoAbs was observed when used in conjunction withoAbs versus control. EGFR, epidermal growth factor receptor;
Figure 3 Meta-analysis of severe infections associated with anti-EGFR MoAbs versus control: ‘leave-one-out’ sensitivity analysis. EGFR,
epidermal growth factor receptor; MoAbs, monoclonal antibodies.
Figure 4 Meta-regression analysis of trends between treatment duration and severe relative risk: symbols: each study is represented
by a circle the diameter of which is proportional to its statistical weight.
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Table 2 Relative risk of severe infectious events with EGFR-MoAbs according to tumor types, EGFR-MoAbs, concomitant
therapies and phases of trials
Groups Studies,
number





CRC 11 276/3801 181/3808 1.42 (1.05 to 1.93) 0.024 0.001
NSCLC 7 199/1341 137/1344 1.45 (1.19 to 1.77) <0.001
Head and neck cancer 4 64/810 43/810 1.48 (1.02 to 2.13) 0.037
Others 4 62/494 77/397 0.72 (0.53 to 0.97) 0.033
Anti-EGFR MoAbs
Cetuximab 21 467/4548 299/4465 1.52 (1.33 to 1.75) <0.001 0.092
Panitumumab 5 134/1898 139/1894 0.99 (0.62 to 1.60) 0.98
Concomitant therapies
Cisplatin 8 233/1690 148/1608 1.48 (1.22 to 1.79) <0.001 0.30
Irinotecan 4 100/942 68/999 1.53 (1.12 to 2.10) 0.008
Oxaliplatin 8 192/2892 172/2847 0.97 (0.58 to 1.61) 0.90
Radiotherapy 3 13/312 11/313 0.99 (0.47 to 2.10) 0.98
Others 3 73/610 39/592 1.80 (1.24 to 2.62) 0.002
Phases of trials
Phase II 9 35/514 21/422 1.26 (0.75 to 2.12) 0.39 0.82
Phase III 17 566/5932 417/593 1.34 (1.08 to 1.67) 0.008
Overall 26 601/6446 438/6359 1.34 (1.10 to 1.62) 0.003 NA
CI, confidence interval; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; MoAbs, monoclonal antibodies; NA, not available; NSCLC, non-small-cell
lung cancer; RR, relative risk.
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irinotecan (RR 1.53, 95%CI: 1.12 to 2.10, P = 0.008),
while anti-EGFR-MoAbs in combination with oxaliplatin
(RR 0.97, 95%CI: 0.58 to 1.61, P = 0.90) and radiotherapy
(RR 0.99, 95%CI: 0.47 to 2.10, P = 0.98) did not increase
the risk of severe infections. However, no significant differ-
ence in RRs of severe infections was found among these
concomitant therapies (P = 0.30). Additionally, we did
sub-group analysis according to the phase of trials
(phase II versus phase III). Patients from phase III tri-
als had an RR of 1.34 (95%CI: 1.08 to 1.67, P = 0.008),
while patients from phase II studies had an RR of 1.26
(95%CI: 0.75 to 2.12, P = 0.39, Table 2).
Risk of severe and fatal infections by specific types
Individual specified and non-specified causes of severe
and fatal infections are listed in Table 3. Of those severe
infections that were specified, the most common events for
severe infections were febrile neutropenia (47.8%). We then
calculated the risk of severe infections stratifying trials
according to specific type of infections. Our results
showed that the use of anti-EGFR MoAbs significantly
increased the risk of severe sepsis (RR 4.30, 95%CI: 1.80
to 10.27, P = 0.001), while a non-significantly increased
risk of febrile neutropenia (RR 1.09, 95%CI: 0.86 to 1.38,
P = 0.68) and pneumonia (RR 1.11, 95%CI: 0.72 to 1.70,P = 0.64) was observed. Of the 24 fatal infections on the
treatment arms and 11 fatal infections on the control
arms, 33.3% and 18.2% were of non-specified etiology,
respectively. Of those fatal infections that were specified,
the most common events for fatal infections were sepsis
(37.5%). When we calculated the risk of fatal infections,
stratifying trials according to specific types of infections, a
non-significantly increased risk of pneumonia (RR 1.46,
95%CI: 0.39 to 5.48, P = 0.56) and sepsis (RR 1.54, 95%CI:
0.50 to 4.74, P = 0.45) was observed (Table 3).
Publication bias
No publication bias was detected for the primary endpoint
of this study (RR of severe infections) by the funnel plot
(Figure 5), Egger’s test and Begg’s test (RR of severe
infections: Begg’s test P = 0.98; Egger’s test P = 0.73).
Discussion
Infections are emerging complications of many MoAbs
and concerns have arisen regarding the risk of infections
with the use of these drugs. In 2007, Rafailidis et al. [45]
performed a systematic review to investigate the incidence
of infectious complications of several MoAbs including
trastuzumab, alemtuzumab, bevacizumab, cetuximab and
rituximab. Based on a single trial, there was a higher rate
of severe infections in patients receiving cetuximab. Then,
Table 3 Severe and fatal infectious events with EGFR-MoAbs by specific types
Infectious events, number/total, number RR (95%CI) P value
EGFR-MoAbs Control
Severe infections
Unspecified 236/2844 144/2829 1.57 (1.16 to 2.13) 0.004
Specified 365/7450 294/7347 1.18 (0.95 to 1.47) 0.14
Febrile neutropenia 287/4551 221/4579 1.09 (0.86 to 1.38) 0.68
Pneumonia 45/1605 37/1527 1.11 (0.72 to 1.70) 0.64
Sepsis 33/1294 6/1241 4.30 (1.80 to 10.27) 0.001
Fatal infections
Unspecified 8/1471 2/1424 2.39 (0.58 to 9.83) 0.23
Specified 16/2486 9/2305 1.43 (0.64 to 3.18) 0.38
Pneumonia 6/1336 3/1261 1.46 (0.39 to 5.48) 0.56
Febrile neutropenia 1/321 1/321 1.00 (0.11 to 9.51) 1.00
Sepsis 9/829 5/732 1.54 (0.50 to 4.74) 0.45
CI, confidence interval; EGFR, epidermal growth factor receptor; MoAbs, monoclonal antibodies; RR, relative risk.
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of 1,083 head and neck cancer patients and found that
cetuximab therapy was not statistically associated with an
increased infection rate in head and neck cancer patients.
As a result, the incidence and risk of infections associated
with anti-EGFR MoAbs has not been well defined.
Our meta-analysis includes a total of 14,060 patients
from twenty six RCTs investigating anti-EGFR MoAbs
for the treatment of cancers. To the best of our know-
ledge, this is the first large study of RCTs demonstrating
a significant increase in the risk of severe infections
(≥grade 3) with the use of anti-EGFR MoAbs in cancer
patients. Our analysis finds that the risk of developing a
severe infection is 1.34-fold higher in patients treated with
anti-EGFR MoAbs, while the use of anti-EGFR MoAbs
does not significantly increase the risk of fatal infections.Figure 5 Funnel plot of standard error by log-odds ratio for severe inSensitivity analysis indicates that the significance estimate
of pooled RRs of severe infection is stable and reliable. We
also performed a meta-regression analysis to investigate
the association between cumulative anti-EGFR MoAbs
exposure and severe infections. The result indicates that
severe infections might possibly occur early in the treat-
ment with anti-EGFR MoAbs. In contrast with our result,
the study conducted by Burtness et al. [5] showed that the
increased risk of neutropenia with cetuximab/cisplatin
compared with placebo/cisplatin was associated with lon-
ger duration of therapy. As a result, further prospective
studies are still needed to address this issue. We also in-
vestigated the outcome of anti-EGFR MoAbs-associated
severe infections. Our study shows that the overall inci-
dence of fatal infections with anti-EGFR MoAbs is 0.8%.
Given that the absolute risk of fatal infections is low, thefections.
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context of overall survival benefits. Because anti-EGFR
MoAbs are increasingly used in cancer patients, it is
particularly important for all health care practitioners and
patients to understand and recognize the risk of severe
and fatal infection.
Because risk factors for severe infections with anti-
EGFR MoAbs are poorly understood, we carried out a
subgroup analysis to identify potential risk factors for
anti-EGFR MoAbs related-infections. When stratified by
tumor type, a significantly increased risk of severe infec-
tions with anti-EGFR MoAbs is observed in colorectal
cancer, non-small-cell lung cancer, and head and neck
cancer. Interestingly, no increased risk of severe infec-
tions is observed in patients with other tumor types re-
ceiving anti-EGFR MoAbs. The risk of severe infections
varies significantly with different tumor types (P = 0.001),
reflecting the nature of the underlying tumor biology or
associated treatment. Notably, our study shows that anti-
EGFR MoAbs significantly increase the risk of severe infec-
tions when used in conjunction with cisplatin or irinotecan.
This result may reflect an interaction between anti-EGFR
MoAbs and certain chemotherapeutic agents in causing se-
vere infections. However, the risk of severe infections dose
not significantly vary with concomitant therapies (P = 0.30).
We also performed sub-group analysis according to anti-
EGFR MoAbs and demonstrated that the use of cetuximab
significantly increases the risk of severe infections, but this
was not the case with panitumumab. Additionally, no
significant differences in the risk of severe infections
with anti-EGFR MoAbs were observed according to the
phase of the trials. Based on our findings, the following
approaches may be considered to reduce the association
of anti-EGFR MoAbs with risk of severe infections. Before
the initiation of anti-EGFR MoAbs, clinicians must fully
treat patients with any active infection and must monitor
patients during the course of anti-EGFR MoAbs treatment.
Clinicians should be cautious when adding anti-EGFR
MoAbs to the therapies for the treatment of colorectal
cancer, non-small-cell lung cancer, and head and neck
cancer, especially when used in conjunction with
cisplatin or irinotecan.
Despite the size of this meta-analysis, our study has
several limitations. First, all included studies were con-
ducted at major academic institutions among patients
with adequate major organ function and may not reflect
the general patient population in the community or pa-
tients with organ dysfunction. It is conceivable that the
true incidences and risk of treatment-related infections
from this study may be underestimated. Second, these
studies were conducted at various institutions by different
investigators internationally and may have potential bias
in reported incidences or specification of severe infections.
Severe infections are not primary outcome measures inthe included studies. The reported incidence of severe
infections has significant heterogeneity among the in-
cluded studies. Nevertheless, we attempted to adjust
for the heterogeneity using a random-effects model to
calculate the incidence of severe and fatal infections.
Third, our study shows that the RR of fatal infection is
higher in patients receiving anti-EGFR MoAbs than in
controls, but is not statistically significant. This obser-
vation might be limited by sample size. Finally, this is a
meta-analysis at study level; therefore, confounding
factors at the patient level cannot be assessed properly
and incorporated into the analysis.
Conclusions
In conclusion, this study has demonstrated that the
addition of anti-EGFR MoAbs to concurrent antineoplastic
therapy is associated with an increased risk of severe infec-
tions in cancer patients. The use of cisplatin or irinotecan
may increase the risk of severe infections associated with
anti-EGFR MoAbs. The increased risk of severe infections
associated with anti-EGFR MoAbs may vary with tumor
types. Early detection and effective management of infec-
tions that can occur with anti-EGFR MoAbs is crucial for
safer use of this drug. Further studies are still recom-
mended to investigate risk reduction and the possible
mechanism of anti-EGFR MoAbs induced infections.
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